DNIB0600A + carboplatin + bevacizumab

This is a combination therapy consisting of **DNIB0600A (lifastuzumab vedotin)**, **carboplatin**, and **bevacizumab**. DNIB0600A is an antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-NaPi2b monoclonal antibody conjugated to the anti-mitotic agent monomethyl auristatin E (MMAE) via a cleavable linker. DNIB0600A targets the sodium-dependent phosphate transporter NaPi2b (encoded by the SLC34A2 gene), overexpressed in many non-squamous non-small cell lung cancers and ovarian carcinomas, and inhibits cell proliferation through microtubule disruption. Carboplatin is a platinum-based DNA-damaging chemotherapeutic agent, while bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. This combination is under clinical investigation for efficacy and safety in patients with advanced ovarian cancer and non-small cell lung cancer, with intravenous administration as the main route[1][3][5][7][9].

Other names

lifastuzumab vedotin + carboplatin + bevacizumab